Abstracts tagged "Cardiovascular disease"

Abstract Number: 1363 • 2014 ACR/ARHP Annual Meeting
Psychosocial Comorbidities Are Independently Associated with Subclinical Atherosclerosis in Rheumatoid Arthritis
Ying Liu¹, Moyses Szklo², Karina Davidson³, Joan Bathon⁴ and Jon Giles³, ¹Internal Medicine, Columbia University Medical Center, New York, NY, ²Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ³Columbia University Medical Center, New York, NY, ⁴Medicine, Columbia University, New York, NY
Background/Purpose: Rheumatoid arthritis (RA) is associated with higher rates of cardiovascular disease (CVD) and subclinical atherosclerosis as well as psychosocial comorbidities, which themselves are associated…
Abstract Number: 838 • 2014 ACR/ARHP Annual Meeting
The Impact of Rheumatoid Arthritis Disease Activity on Cardiovascular Disease Risk: What Is the Role of the Flare?
Elena Myasoedova¹, Arun K. Chandran², Birkan İlhan³, Brittny T. Major⁴, C. John Michet III², Eric L. Matteson² and Cynthia S. Crowson⁴, ¹Internal Medicine and Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkey, ⁴Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular disease (CVD). Longitudinal studies assessing the effect of changes of RA activity on…
Abstract Number: 156 • 2014 ACR/ARHP Annual Meeting
Colchicine and the Risk of Acute Cardiovascular (CV) Events Among Gout Patients: The New York Department of Veterans Affairs Retrospective Cohort Study
Daria B. Crittenden^1,2, Jessica N. Kimmel^1,2, Virginia C. Pike^1,2, Rebecca Boas^1,2, Daniel Diaz^1,2, Cilian J. White^1,2, Michael DeBerardine^1,2, Grace Kim^1,2, Pajazit Morina^1,2, Avni Shah^1,2, Binita Shah^2,3, Steven P. Sedlis^2,3, Jeffrey D. Greenberg^2,4, Craig T. Tenner^2,5, Christopher J. Swearingen^1,6, Svetlana Krasnokutsky Samuels^1,2, Bruce N. Cronstein¹ and Michael H. Pillinger^1,2, ¹NYU School of Medicine, Division of Rheumatology, New York, NY, ²VA New York Harbor Health Care System, New York, NY, ³NYU School of Medicine, Division of Cardiology, New York, NY, ⁴NYU School of Medicine, New York, NY, ⁵NYU School of Medicine, Department of Medicine, New York, NY, ⁶Department of Pediatrics and Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR
Background/Purpose: Gout patients are at increased risk for CV disease, possibly owing to chronic inflammation. Colchicine is commonly used in gout, and inhibits inflammatory cell…
Abstract Number: 2445 • 2014 ACR/ARHP Annual Meeting
A Distinct Profile of Circulating Microparticles Is Associated with Disease Features in Rheumatoid Arthritis Patients and Impairs Endothelial Functionality in Vitro
Javier Rodríguez-Carrio¹, Mercedes Alperi-López², Patricia López¹, Sara Alonso-Castro², Santiago Rubén Carro-Esteban¹, Javier Ballina-García² and Ana Suárez¹, ¹Area of Immunology, Department of Functional Biology, University of Oviedo, Oviedo, Spain, ²Rheumatology Department, Hospital Universitario Central de Asturias, Oviedo, Spain
Background/Purpose Cell-derived microparticles (MPs) could be considered biomarkers of cell damage and activation and they are thought to have a role in cardiovascular (CV) and inflammatory…
Abstract Number: 1846 • 2014 ACR/ARHP Annual Meeting
The Association Between Hydroxychloroquine Treatment and Cardiovascular Morbidity Among Rheumatoid Arthritis Patients
Michael Shapiro¹ and Yair Levy², ¹Haim Lebanon 55, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ²Internal Medicine E, Meir Medical Center, Kfar Saba, Israel
Background/Purpose: Accelerated atherosclerosis and cardiovascular disease are the main causes of mortality in Rheumatoid Arthritis (RA). The anti-malarial drug Hydroxychloroquine (HCQ) has long been used…
Abstract Number: 1362 • 2014 ACR/ARHP Annual Meeting
Impact of Rapid Attainment of Stringent Measures of Efficacy in Rheumatoid Arthritis on Patient-Reported Outcomes
EA Alemao¹, S Joo², S Banerjee¹, P Emery³ and M Weinblatt⁴, ¹Bristol-Myers Squibb, Princeton, NJ, ²Bristol-Myers Squibb, Hopewell, NJ, ³University of Leeds, Leeds, United Kingdom, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: Treatment guidelines in RA recommend that therapies aim to reach a target of remission or low disease activity (LDA) and that these targets should…
Abstract Number: 836 • 2014 ACR/ARHP Annual Meeting
Categorical Change in 6MWD in Patients with Connective Tissue Disease Associated Pulmonary Arterial Hypertension Receiving Ambrisentan over 3-Years
Aryeh Fischer¹, Virginia D. Steen², Steven Nathan³, Hunter Gillies⁴, James Tislow⁵ and Chris Blair⁶, ¹Rheumatology / ILD Program, National Jewish Health, Denver, CO, ²Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ³Heart Failure/Transplant, Inova Medical Group, Falls Church, VA, ⁴Clinical Research - Cardiovascular, Gilead Sciences, Inc., Foster City, CA, ⁵Medical Affairs, Gilead Sciences, Inc., Foster City, CA, ⁶Biostatistics, Gilead Sciences, Inc., Foster City, CA
Background/Purpose: The 6MWD is a valuable tool for evaluating response to therapy in patients with pulmonary arterial hypertension and may be considered a surrogate measure…
Abstract Number: 154 • 2014 ACR/ARHP Annual Meeting
Cimt in Individuals with Rheumatoid Arthritis Compared to Individuals with Type2 Diabetes
Helen Pahau Sr.^1,2, Leanne Short³, Brian Haluskas⁴, Vibeke Videm⁵ and Ranjeny Thomas⁶, ¹Diamantina Institute, The University of Queensland, Woolloongabba, Australia, ²Diamantina Institute, University of Queensland Diamantina Institute, Brisbane, Australia, ³Cardiovascular Imaging Research Centre, University of Queensland, Woolloongabba, Australia, ⁴Cardiovascular Imaging Research Centre, the University of Queensland, Woolloongabba, Australia, ⁵Department of Laboratory Medicine, Children's and Women's Health, Norwegian University of Science and Technology, and Department of Immunology and Transfusion Medicine, Trondheim University Hospital,, Trondheim, Norway, ⁶University of Queensland Diamantina Institute, Brisbane, Australia
Background/Purpose It is well known that patients with RA or Type 2 diabetes (T2DM) have increased risk of atherosclerosis and CVD. Carotid ultrasound measurement of…
Abstract Number: 2452 • 2014 ACR/ARHP Annual Meeting
Protective Effect of the IL33 rs3939286 Gene Polymorphism in the Development of Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis
Raquel López-Mejías¹, Fernanda Genre¹, Mercedes García-Bermúdez², Alfonso Corrales¹, Carlos González-Juanatey³, Begoña Ubilla¹, J. Llorca⁴, Encarnación Amigo⁵, Jose A. Miranda-Filloy⁶, Trinitario Pina Murcia¹, Ricardo Blanco⁷, Santos Castañeda⁸, Javier Martin⁹ and Miguel A González-Gay¹, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, ²Immunology and Cellular Biology, Instituto de Parasitologia y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, ³Hospital Universitario Lucus Augusti. Cardiology Division, Lugo, Spain, ⁴Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, ⁵Hospital Universitario Lucus Augusti, Rheumatology Division, Lugo, Spain, ⁶Rheumatology, Division of Rheumatology, Hospital Lucus Augusti, Lugo, Spain, ⁷Hospital Marques de Valdecilla, Santander, Spain, ⁸Rheumatology, Hospital Universitario de La Princesa, IISP, Madrid, Spain, ⁹Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain
Background/Purpose: Rheumatoid arthritis (RA) is a complex inflammatory disease characterized by chronic inflammation, accelerated atherosclerosis and increased cardiovascular (CV) mortality. Interleukin 33 (IL-33) is a…
Abstract Number: 1769 • 2014 ACR/ARHP Annual Meeting
Abdominal Visceral Adipose Tissue Measured By DXA As a Novel Surrogate Marker of Cardiovascular Risk in Primary Necrotizing Vasculitides
Bertrand Dunogué¹, Karine Briot², Sami Kolta³, Alexis Regent⁴, Pascal Cohen⁵, Alice Berezne⁶, Xavier Puéchal⁵, Claire Le Jeunne⁵, Luc Mouthon⁵, Christian Roux⁷, Loïc Guillevin for the French Vasculitis Study Group⁵ and Benjamin Terrier⁸, ¹Internal Medicine, Hôpital Cochin, Paris, France, ²Cochin Hospital, Paris Descartes University, Paris, France, ³Rheumatology B, Paris Descartes University, Cochin hospital, Paris, France, ⁴Internal Medicine, Institut Cochin, INSERM U1016, CNRS UMR 8104, Université Paris Descartes, Paris, France, Paris, France, ⁵National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ⁶Paris Descartes University, Internal Medicine department, Cochin Hospital, Paris, France, ⁷Paris Descartes University, Cochin Hospital, Paris, France, ⁸National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France
Background/Purpose Studies have shown a strong prevalence of cardiovascular events among patients with primary necrotizing vasculitides. Recent studies indicate that visceral adipose tissue (VAT) is…
Abstract Number: 1361 • 2014 ACR/ARHP Annual Meeting
Rheumatologists’ Attitudes on Cardiovascular Risk and Lipid Screening in Patients with Rheumatoid Arthritis at an Academic Medical Center
Ashwini Komarla¹ and Alexis Ogdie², ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Cardiovascular (CV) disease is a major cause of morbidity and mortality in the rheumatoid arthritis (RA) population. Thus, the recognition and management of cardiovascular…
Abstract Number: 818 • 2014 ACR/ARHP Annual Meeting
Incident Rheumatoid Arthritis and Risk of Mortality Among Women Followed Prospectively from 1976 to 2010 in the Nurses’ Health Study
Jeffrey A. Sparks¹, Shun-Chiao Chang^1,2, Katherine P. Liao¹, Bing Lu¹, Daniel H. Solomon¹, Karen H. Costenbader¹ and Elizabeth W. Karlson¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose RA has been associated with increased mortality compared to general population estimates. Previous studies were limited due to the inability to directly compare RA…
Abstract Number: 96 • 2014 ACR/ARHP Annual Meeting
Comparison of Cardiovascular Risk Factor Management in Patients with RA and Matched Non-RA Patients
H Cawston¹, E Alemao², F Bourhis¹, T Le³, M Al⁴, M Rutten-van Molken⁴, Katherine Liao⁵ and DH Solomon⁶, ¹OptumInsight, Nanterre, France, ²Bristol-Myers Squibb, Princeton, NJ, ³Bristol-Myers Squibb, Hopewell, NJ, ⁴Erasmus University, Rotterdam, Netherlands, ⁵Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁶Brigham and Women's Hospital, Boston, MA
Background/Purpose : The relative risk of acute myocardial infarction in RA patients (pts) has been shown to range from 1.5 to 2.0, with a 1.4–2.7-fold…
Abstract Number: 2623 • 2013 ACR/ARHP Annual Meeting
A CT Evaluation Of Pulmonary and Cardiac Lesions In BEHÇET’S Syndrome Patients Without Pulmonary Symptoms
Emire Seyahi¹, Deniz Cebi Olgun², SerdaL Ugurlu¹, Idil Hanci³, Reona Takahashi⁴ and Hasan Yazici¹, ¹Division of Rheumatology,Department of Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²Department of Radiology,, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ³Department of Neurology, Krankrenhaus Nordwest, Frankfurt am Main, Frankfurt, Germany, ⁴Department of Internal Medicine, Division of Rheumatology, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey
Background/Purpose: In Behçet’s syndrome (BS) patients with symptomatic pulmonary artery involvement (PAI) varying and multiple pulmonary parenchymal and cardiac lesions can be seen in thorax CT…
Abstract Number: 1576 • 2013 ACR/ARHP Annual Meeting
Type I Interferon-Mediated Skewing Of The Serotonin Synthesis In Systemic Lupus Erythematosus Is Associated To Cardiovascular Disease
Christian Lood¹, Helena Tydén¹, Birgitta Gullstrand², Cecilia Klint³, Christina Wenglén³, Christoffer T. Nielsen⁴, Niels H. H. Heegaard⁵, Andreas Jönsen¹ and Anders A. Bengtsson¹, ¹Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden, ²Department of Laboratory Medicine, Section of Microbiology, Immunology and Glycobiology, Lund University, Lund, Sweden, ³R&D, AnaMar AB, Lund, Sweden, ⁴Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen S, Denmark, ⁵Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen, Denmark
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease characterized by increased expression of type I interferons (IFNs). Indoleamine 2,3-dioxygenase (IDO), a type I…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].